Urinary water clearance after infusion of conivaptan, a combined vasopressin V1a and V2 receptor antagonist, in patients with NYHA class III/IV heart failure

被引：0
|
作者：
Painchaud, CA
Ghazzi, MM
Selaru, P
Bichet, DG
Chartier, KK
Udelson, JE
机构：
[1] Parke Davis Pharmaceut Res, Ann Arbor, MI USA
[2] Hosp Sacre Coeur Montreal, Montreal, PQ, Canada
[3] New England Med Ctr, Boston, MA 02111 USA
来源：
CIRCULATION | 2000年 / 102卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2603
引用
收藏
页码：535 / 535
页数：1
相关论文
共 50 条
  • [31] A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)
    Wada, Koh-ichi
    Matsuyawa, Utane
    Fujimori, Akira
    Arai, Yukinori
    Sudoh, Katsumi
    Sasamata, Masao
    Miyata, Keiji
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2007, 30 (01) : 91 - 95
  • [32] Differentiation of Arginine Vasopressin Antagonistic Effects by Selective V2 versus Dual V2/V1a Receptor Blockade in a Preclinical Heart Failure Model
    Mondritzki, Thomas
    Kolkhof, Peter
    Sabbah, Hani N.
    Gheorghiade, Mihai
    Fuerstner, Chantal
    Schmeck, Carsten
    Siedentop, Harald
    Schaefer, Stefan
    Truebel, Hubert
    AMERICAN JOURNAL OF THERAPEUTICS, 2011, 18 (01) : 31 - 37
  • [33] Pharmacological characterization of YM471, a novel potent vasopressin V1A and V2 receptor antagonist
    Tsukuda, J
    Tahara, A
    Tomura, Y
    Wada, K
    Kusayama, T
    Ishii, N
    Aoki, M
    Yatsu, T
    Uchida, W
    Taniguchi, N
    Tanaka, A
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 446 (1-3) : 129 - 138
  • [34] Renal effects of a novel dual acting V1a/V2 vasopressin receptor antagonist: comparison with furosemide
    Kolkhof, P.
    Stasch, J. P.
    Pook, E.
    Schmeck, C.
    Fuerstner, C.
    Albrecht-Kuepper, B.
    EUROPEAN HEART JOURNAL, 2011, 32 : 788 - 789
  • [35] A Novel Balanced Dual Vasopressin V1a/V2 Receptor Antagonist for Treatment of Congestive Heart Failure: Results From a First-in-Man Study
    Pimenta, Eduardo
    Jensen, Markus
    Jung, David
    Lobmeyer, Maximilian
    Schmitt, Walter
    Schaumann, Frank
    Boxnick, Stefanie
    Truebel, Hubert
    CIRCULATION, 2017, 136
  • [36] LIXIVAPTAN Vasopressin V2 Receptor Antagonist Treatment of Heart Failure Treatment of Hyponatremia
    Daifallah, S.
    Zmily, H. D.
    Alqwasmi, A. H.
    Zayed, H.
    Ghali, J. K.
    DRUGS OF THE FUTURE, 2011, 36 (05) : 359 - 370
  • [37] Pharmacological characterization of YMO87, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist
    Tahara, A
    Saito, M
    Sugimoto, T
    Tomura, Y
    Wada, K
    Kusayama, T
    Tsukada, J
    Ishii, N
    Yatsu, T
    Uchida, W
    Tanaka, A
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 357 (01) : 63 - 69
  • [38] In vivo and in vitro characterisation of a nonpeptide vasopressin V1A and V2 receptor antagonist (YM087) in the rat
    Risvanis, J
    Naitoh, M
    Johnston, CI
    Burrell, LM
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 381 (01) : 23 - 30
  • [39] Vasopressin V2 Receptor Antagonist Tolvaptan is Effective in Heart Failure Patients With Reduced Cardiac Systolic Function
    Suzuki, Satoshi
    Yoshihisa, Akiomi
    Yamaki, Takayoshi
    Sugimoto, Koichi
    Kunii, Hiroyuki
    Nakazato, Kazuhiko
    Abe, Yukihiko
    Saito, Tomiyoshi
    Ohwada, Takayuki
    Saitoh, Shu-ichi
    Kubota, Isao
    Takeishi, Yasuchika
    CIRCULATION, 2013, 128 (22)
  • [40] Conivaptan, a Selective Arginine Vasopressin V1a and V2 Receptor Antagonist Attenuates Global Cerebral Edema Following Experimental Cardiac Arrest via Perivascular Pool of Aquaporin-4
    Shin Nakayama
    Mahmood Amiry-Moghaddam
    Ole Petter Ottersen
    Anish Bhardwaj
    Neurocritical Care, 2016, 24 : 273 - 282
12345